Samaneh Mozafarpoor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Samaneh Mozafarpoor has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Azadeh Goodarzi
Department of Dermatology, Hazrat Fatemeh Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Islamic Republic of Iran.
10 shared publications - Afsaneh Sadeghzadeh Bazargan
Department of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine Iran University of Medical Sciences (IUMS) Tehran Iran
3 shared publications - Farnoosh Seirafianpour
Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran
3 shared publications - Arash Pour Mohammad
Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, USA
2 shared publications - Elham Ziaeifar
Department of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine Iran University of Medical Sciences Tehran Iran
2 shared publications - Niloufar Najar Nobari
Skin Repair Research Center, Jordan Dermatology and Hair Transplantation Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications
Latest Publications
- Open Access
- 11 December 2025
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 24 (12) , e70602
The Efficacy of Laser Therapy in Melasma Treatment: A Systematic Review and Meta‐Analysis
Introduction: Laser treatment is one of the most common methods currently used to treat melasma. Here in, we reviewed RCTs with at least one laser therapy arm used in net form for treatment, so as to assess the use of laser therapy for melasma treatment with a degree of certainty. Methods: A systematic literature search was performed on the effectiveness of laser therapy for melasma treatment in the period from 2010 to 2024 using the keywords melasma , laser , and efficacy in the title. Finally, a meta‐analysis was conducted using the mean and standard deviation of the Melasma Area and Severity Index (MASI) variations before and after each session of laser therapy in different studies. Results: Sixteen RCTs on the efficacy, safety, and recurrence associated with laser therapy for melasma were eventually included and assessed. A total of 471 patients with a mean age of 35.3–46.4 years were examined. The 1064‐nm Q‐Switched Nd:YAG Laser (QSNd:YAG) was the most common laser investigated in the studies. There were 2–12 treatment sessions, with 1–4‐week intervals, and the patients' follow‐up period was 2–6 months. The use of SSR (Super Skin Rejuvenation, 540 nm), low‐energy QSNDY, and pixel‐Er:YAG (Erbium YAG) for five sessions at 3‐week intervals showed a very significant decrease in the modified MASI (mMASI) score ( p < 0.001). Pixel‐Er:YAG showed the maximum mMASI reduction and homogeneity ( p > 0.001). Epidermal melasma had the best results with SSR and PQSND (Y Pixel Q‐Switched Nd:YAG Laser) ( p < 0.001). Conclusion: Among the reviewed RCTs, the largest weight was assigned to a 2014 study that examined 40 patients (4.79% weight). The standardized variation of the mean MASI was negative in all studies, except for a 2011 study, which had the lowest weight among the studies (2.84%), indicating the mitigation of symptoms following laser therapy. A meta‐analysis of 16 research studies (26 treatment arms) was performed to determine the efficacy of laser therapy for melasma. Treatment resulted in a significant improvement in MASI scores, with a pooled standardized mean difference of 0.88 (95% CI: 0.65–1.11, p < 0.00001). Due to moderate‐to‐high heterogeneity ( I 2 = 68.4%), a random‐effects model was employed. Overall, the findings indicate that for the majority of patients, laser therapy reduces pigmentation and lesion severity.
- 11 December 2025
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 24 (12) , e70602
Open AccessThe Efficacy of Laser Therapy in Melasma Treatment: A Systematic Review and Meta‐Analysis
Introduction: Laser treatment is one of the most common methods currently used to treat melasma. Here in, we reviewed RCTs with at least one laser therapy arm used in net form for treatment, so as to assess the use of laser therapy for melasma treatment with a degree of certainty. Methods: A systematic literature search was performed on the effectiveness of laser therapy for melasma treatment in the period from 2010 to 2024 using the keywords melasma , laser , and efficacy in the title. Finally, a meta‐analysis was conducted using the mean and standard deviation of the Melasma Area and Severity Index (MASI) variations before and after each session of laser therapy in different studies. Results: Sixteen RCTs on the efficacy, safety, and recurrence associated with laser therapy for melasma were eventually included and assessed. A total of 471 patients with a mean age of 35.3–46.4 years were examined. The 1064‐nm Q‐Switched Nd:YAG Laser (QSNd:YAG) was the most common laser investigated in the studies. There were 2–12 treatment sessions, with 1–4‐week intervals, and the patients' follow‐up period was 2–6 months. The use of SSR (Super Skin Rejuvenation, 540 nm), low‐energy QSNDY, and pixel‐Er:YAG (Erbium YAG) for five sessions at 3‐week intervals showed a very significant decrease in the modified MASI (mMASI) score ( p < 0.001). Pixel‐Er:YAG showed the maximum mMASI reduction and homogeneity ( p > 0.001). Epidermal melasma had the best results with SSR and PQSND (Y Pixel Q‐Switched Nd:YAG Laser) ( p < 0.001). Conclusion: Among the reviewed RCTs, the largest weight was assigned to a 2014 study that examined 40 patients (4.79% weight). The standardized variation of the mean MASI was negative in all studies, except for a 2011 study, which had the lowest weight among the studies (2.84%), indicating the mitigation of symptoms following laser therapy. A meta‐analysis of 16 research studies (26 treatment arms) was performed to determine the efficacy of laser therapy for melasma. Treatment resulted in a significant improvement in MASI scores, with a pooled standardized mean difference of 0.88 (95% CI: 0.65–1.11, p < 0.00001). Due to moderate‐to‐high heterogeneity ( I 2 = 68.4%), a random‐effects model was employed. Overall, the findings indicate that for the majority of patients, laser therapy reduces pigmentation and lesion severity.
- Open Access
- 12 March 2024
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 23 (6) , 2220-2230
Evaluation of efficacy and safety of vitiligo treatment with micro‐needling combined with N‐Acetylcysteine and micro‐needling alone: A double‐blinded randomized controlled clinical trial
Introduction: Vitiligo is a skin pigmentation disorder caused by the selective degradation of melanocytes. This study investigates the therapeutic effects of microneedling with and without N‐acetylcysteine (NAC) in patients with persistent and limited vitiligo.Method: This research employed a clinical trial design with double‐blind randomization. Individuals affected by vitiligo and seeking treatment at Rasool Akram Medical Complex were divided into two separate treatment groups. In the intervention group, 24 affected areas underwent meso‐microneedling using 5% NAC ampoules over six sessions, in addition to the application of 4.7% NAC cream once daily on the specified area. Conversely, the control group, consisting of 22 lesions, underwent microneedling using distilled water during six sessions. The severity of lesions and the extent of repigmentation were gauged using the Modified VETI Score. Assessment of treatment efficacy was determined through both physician evaluations and patient feedback.Results: Twenty patients with a mean age of 36.4 years were recruited. The mean percentage of lesions and their intensity were significantly improved 2 weeks after the third session and 1 month after the end of the treatment (p < 0.01). There was no statistically significant difference between the intervention and control groups. Gender, age, family history, duration of disease, duration of disease stability, and history of hypothyroidism had no statistically significant relationship with patients' treatment outcomes (p > 0.05).Conclusion: Microneedling with or without the application of NAC appears to be an effective treatment option for persistent vitiligo lesions. However, despite the higher improvement rate with the application of NAC, the difference was not significant.
- 12 March 2024
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 23 (6) , 2220-2230
Open AccessEvaluation of efficacy and safety of vitiligo treatment with micro‐needling combined with N‐Acetylcysteine and micro‐needling alone: A double‐blinded randomized controlled clinical trial
Introduction: Vitiligo is a skin pigmentation disorder caused by the selective degradation of melanocytes. This study investigates the therapeutic effects of microneedling with and without N‐acetylcysteine (NAC) in patients with persistent and limited vitiligo.Method: This research employed a clinical trial design with double‐blind randomization. Individuals affected by vitiligo and seeking treatment at Rasool Akram Medical Complex were divided into two separate treatment groups. In the intervention group, 24 affected areas underwent meso‐microneedling using 5% NAC ampoules over six sessions, in addition to the application of 4.7% NAC cream once daily on the specified area. Conversely, the control group, consisting of 22 lesions, underwent microneedling using distilled water during six sessions. The severity of lesions and the extent of repigmentation were gauged using the Modified VETI Score. Assessment of treatment efficacy was determined through both physician evaluations and patient feedback.Results: Twenty patients with a mean age of 36.4 years were recruited. The mean percentage of lesions and their intensity were significantly improved 2 weeks after the third session and 1 month after the end of the treatment (p < 0.01). There was no statistically significant difference between the intervention and control groups. Gender, age, family history, duration of disease, duration of disease stability, and history of hypothyroidism had no statistically significant relationship with patients' treatment outcomes (p > 0.05).Conclusion: Microneedling with or without the application of NAC appears to be an effective treatment option for persistent vitiligo lesions. However, despite the higher improvement rate with the application of NAC, the difference was not significant.
- 16 September 2022
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 21 (12) , 7219-7221
Can hair cast be a helpful dermoscopic diagnostic clue in telogen effluvium?
- 16 September 2022
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 21 (12) , 7219-7221
Can hair cast be a helpful dermoscopic diagnostic clue in telogen effluvium?
- Open Access
- 22 April 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (8)
Whole-transcriptome sequencing–based concomitant detection of viral and human genetic determinants of cutaneous lesions
Severe viral infections of the skin can occur in patients with inborn errors of immunity (IEI). We report an all-in-one whole-transcriptome sequencing–based method by RNA-Seq on a single skin biopsy for concomitantly identifying the cutaneous virome and the underlying IEI. Skin biopsies were obtained from healthy and lesional skin from patients with cutaneous infections suspected to be of viral origin. RNA-Seq was utilized as the first-tier strategy for unbiased human genome-wide rare variant detection. Reads unaligned to the human genome were utilized for the exploration of 926 viruses in a viral genome catalog. In 9 families studied, the patients carried pathogenic variants in 6 human IEI genes, including IL2RG , WAS , CIB1 , STK4 , GATA2 , and DOCK8 . Gene expression profiling also confirmed pathogenicity of the human variants and permitted genome-wide homozygosity mapping, which assisted in identification of candidate genes in consanguineous families. This automated, online, all-in-one computational pipeline, called VirPy, enables simultaneous detection of the viral triggers and the human genetic variants underlying skin lesions in patients with suspected IEI and viral dermatosis.
- 22 April 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (8)
Open AccessWhole-transcriptome sequencing–based concomitant detection of viral and human genetic determinants of cutaneous lesions
Severe viral infections of the skin can occur in patients with inborn errors of immunity (IEI). We report an all-in-one whole-transcriptome sequencing–based method by RNA-Seq on a single skin biopsy for concomitantly identifying the cutaneous virome and the underlying IEI. Skin biopsies were obtained from healthy and lesional skin from patients with cutaneous infections suspected to be of viral origin. RNA-Seq was utilized as the first-tier strategy for unbiased human genome-wide rare variant detection. Reads unaligned to the human genome were utilized for the exploration of 926 viruses in a viral genome catalog. In 9 families studied, the patients carried pathogenic variants in 6 human IEI genes, including IL2RG , WAS , CIB1 , STK4 , GATA2 , and DOCK8 . Gene expression profiling also confirmed pathogenicity of the human variants and permitted genome-wide homozygosity mapping, which assisted in identification of candidate genes in consanguineous families. This automated, online, all-in-one computational pipeline, called VirPy, enables simultaneous detection of the viral triggers and the human genetic variants underlying skin lesions in patients with suspected IEI and viral dermatosis.
- 2 February 2022
- Published by Springer Nature in Lasers in Medical Science
- Vol. 37 (4) , 2111-2122
Systematic review and meta-analysis of randomized clinical trials comparing efficacy, safety, and satisfaction between ablative and non-ablative lasers in facial and hand rejuvenation/resurfacing
Skin aging inevitably begins from the very early days of life. The lasers used in skin rejuvenation are mainly of two types: ablative and non-ablative. This meta-analysis aimed at comparing ablative with non-ablative lasers in terms of their efficacy and safety in skin rejuvenation. Articles published by March 15, 2020 in Embase, Medline (PubMed), Scopus, Cochrane, and clinicalTrials.gov were searched. The inclusion criteria included randomized controlled clinical trials (RCTs) in English using ablative and non-ablative lasers and comparing their safety and efficiency in wrinkle improvement and photoaging therapy. Out of 1353 extracted articles, 11 were selected for qualitative synthesis and of these, 4 were quantitatively analyzed. Different modes of various lasers were implemented; the ablative lasers included Erbium: yttrium–aluminium-garnet (Er:YAG) and CO2, besides the non-ablative lasers, comprised Ytterbium/Erbium, Erbium: Glass, neodymium: yttrium–aluminum-garnet (Nd:YAG), and alexandrite. Pooled analyses on 124 participants showed insignificant differences between ablative and non-ablative lasers in the likelihood of excellent improvement with an odds ratio of 0.83 (95% CI: 0.24, 2.83). The analyses also showed good improvement with an odds ratio of 0.88 (95% CI: 0.44, 1.78), fair improvement with an odds ratio of 1.13 (95% CI: 0.56, 2.26) and side effects with an odds ratio of 0.82 (95% CI: 0.43, 1.56). The efficacy and safety of ablative laser were not higher than those of non-ablative laser in skin rejuvenation. Given the small samples of the included articles, it is recommended that further high-quality RCTs be conducted using larger samples to confirm this conclusion.
- 2 February 2022
- Published by Springer Nature in Lasers in Medical Science
- Vol. 37 (4) , 2111-2122
Systematic review and meta-analysis of randomized clinical trials comparing efficacy, safety, and satisfaction between ablative and non-ablative lasers in facial and hand rejuvenation/resurfacing
Skin aging inevitably begins from the very early days of life. The lasers used in skin rejuvenation are mainly of two types: ablative and non-ablative. This meta-analysis aimed at comparing ablative with non-ablative lasers in terms of their efficacy and safety in skin rejuvenation. Articles published by March 15, 2020 in Embase, Medline (PubMed), Scopus, Cochrane, and clinicalTrials.gov were searched. The inclusion criteria included randomized controlled clinical trials (RCTs) in English using ablative and non-ablative lasers and comparing their safety and efficiency in wrinkle improvement and photoaging therapy. Out of 1353 extracted articles, 11 were selected for qualitative synthesis and of these, 4 were quantitatively analyzed. Different modes of various lasers were implemented; the ablative lasers included Erbium: yttrium–aluminium-garnet (Er:YAG) and CO2, besides the non-ablative lasers, comprised Ytterbium/Erbium, Erbium: Glass, neodymium: yttrium–aluminum-garnet (Nd:YAG), and alexandrite. Pooled analyses on 124 participants showed insignificant differences between ablative and non-ablative lasers in the likelihood of excellent improvement with an odds ratio of 0.83 (95% CI: 0.24, 2.83). The analyses also showed good improvement with an odds ratio of 0.88 (95% CI: 0.44, 1.78), fair improvement with an odds ratio of 1.13 (95% CI: 0.56, 2.26) and side effects with an odds ratio of 0.82 (95% CI: 0.43, 1.56). The efficacy and safety of ablative laser were not higher than those of non-ablative laser in skin rejuvenation. Given the small samples of the included articles, it is recommended that further high-quality RCTs be conducted using larger samples to confirm this conclusion.
- 17 October 2021
- Published by Wiley in Dermatologic Therapy
- Vol. 34 (6) , e15159
Applications of microneedling for various dermatologic indications with a special focus on pigmentary disorders: A comprehensive review study
Microneedling can accelerate skin repair through numerous complex processes triggered by micro‐injuries it produces on the skin surface with very thin needles. The current growth in the application of microneedling in the treatment of cutaneous diseases can be explained by its numerous effects on the skin as reported in the literature. Despite the numerous studies conducted on the application of microneedling in the treatment of skin lesions, its effects on pigmented skin lesions have remained relatively unexplored. The present review comprises an examination of the evidence for the application of microneedling in skin diseases in general and a comprehensive review of the applications of microneedling in pigmentation disorders. The review involved a search of all clinical studies, including trials, case reports, and case series, in the databases MEDLINE/PubMed and Google Scholar using the following keywords: “microneedling,” “dermal needling,” “percutaneous collagen induction,” “skin needling,” “dermaroller,” and “dermatology disorder.” Pertinent data were extracted from all relevant articles published from 1990 to April 2021, and focused on the application of microneedling in the treatment of pigmented skin lesions. Despite the limited number of available studies, evidence suggests the effectiveness and safety of microneedling in treating vitiligo, melasma, and periorbital hypermelanosis. It is noteworthy that the combination of any type of non‐aggressive needing technique with other effective therapies (especially topical agents and mesotherapy) yields more promising therapeutic results than single therapy for melasma, dark cycles, and vitiligo as the prototype of pigmentary disorders. However, single needling therapy is significantly effective, too.
- 17 October 2021
- Published by Wiley in Dermatologic Therapy
- Vol. 34 (6) , e15159
Applications of microneedling for various dermatologic indications with a special focus on pigmentary disorders: A comprehensive review study
Microneedling can accelerate skin repair through numerous complex processes triggered by micro‐injuries it produces on the skin surface with very thin needles. The current growth in the application of microneedling in the treatment of cutaneous diseases can be explained by its numerous effects on the skin as reported in the literature. Despite the numerous studies conducted on the application of microneedling in the treatment of skin lesions, its effects on pigmented skin lesions have remained relatively unexplored. The present review comprises an examination of the evidence for the application of microneedling in skin diseases in general and a comprehensive review of the applications of microneedling in pigmentation disorders. The review involved a search of all clinical studies, including trials, case reports, and case series, in the databases MEDLINE/PubMed and Google Scholar using the following keywords: “microneedling,” “dermal needling,” “percutaneous collagen induction,” “skin needling,” “dermaroller,” and “dermatology disorder.” Pertinent data were extracted from all relevant articles published from 1990 to April 2021, and focused on the application of microneedling in the treatment of pigmented skin lesions. Despite the limited number of available studies, evidence suggests the effectiveness and safety of microneedling in treating vitiligo, melasma, and periorbital hypermelanosis. It is noteworthy that the combination of any type of non‐aggressive needing technique with other effective therapies (especially topical agents and mesotherapy) yields more promising therapeutic results than single therapy for melasma, dark cycles, and vitiligo as the prototype of pigmentary disorders. However, single needling therapy is significantly effective, too.
- 2 June 2021
- Published by Wiley in Dermatologic Therapy
- Vol. 34 (4) , e15015
Mucocutaneous manifestations of patients with chronic kidney disease under hemodialysis: A cross‐sectional study of 49 patients
Chronic Kidney Disease (CKD) is a common medical problem with well-known dermatologic manifestations, some of which highly disturb the patients' quality of life. This cross-sectional study was designed to identify the prevalence and type of cutaneous involvement in CKD patients. The skin manifestations of 49 patients with CKD undergoing hemodialysis at Akhavan Hospital in Kashan, Iran, were recorded over two months. Diabetes (35%) was the most common cause of Chronic Renal Failure (CRF) in the patients, and the most common skin manifestations were xerosis (95.9%), uremic pigmentation (89.8%), scleral discoloration (87.8%), dental discoloration (85.2% among the patients with natural teeth), dry mouth (65.3%), varicosity (61.2%), pruritus (57.1%), skin atrophy (49%), lentigo (46.9%), subungual hyperkeratosis (42.9%), half and half nail dystrophy (34.7%) and purpura (26.5%). Mucocutaneous involvement has a very high prevalence in CKD patients undergoing hemodialysis, and some of the cases are medically and cosmetically disturbing; therefore, with better knowledge about the type and prevalence of these involvements, the consequences can be better predicted and managed. Further studies are recommended to be conducted on the association between these signs and CKD grade, and clinical trials are also required for establishing the treatment options available for these signs and then assessing the patients' quality of life as a primary outcome measure.
- 2 June 2021
- Published by Wiley in Dermatologic Therapy
- Vol. 34 (4) , e15015
Mucocutaneous manifestations of patients with chronic kidney disease under hemodialysis: A cross‐sectional study of 49 patients
Chronic Kidney Disease (CKD) is a common medical problem with well-known dermatologic manifestations, some of which highly disturb the patients' quality of life. This cross-sectional study was designed to identify the prevalence and type of cutaneous involvement in CKD patients. The skin manifestations of 49 patients with CKD undergoing hemodialysis at Akhavan Hospital in Kashan, Iran, were recorded over two months. Diabetes (35%) was the most common cause of Chronic Renal Failure (CRF) in the patients, and the most common skin manifestations were xerosis (95.9%), uremic pigmentation (89.8%), scleral discoloration (87.8%), dental discoloration (85.2% among the patients with natural teeth), dry mouth (65.3%), varicosity (61.2%), pruritus (57.1%), skin atrophy (49%), lentigo (46.9%), subungual hyperkeratosis (42.9%), half and half nail dystrophy (34.7%) and purpura (26.5%). Mucocutaneous involvement has a very high prevalence in CKD patients undergoing hemodialysis, and some of the cases are medically and cosmetically disturbing; therefore, with better knowledge about the type and prevalence of these involvements, the consequences can be better predicted and managed. Further studies are recommended to be conducted on the association between these signs and CKD grade, and clinical trials are also required for establishing the treatment options available for these signs and then assessing the patients' quality of life as a primary outcome measure.
- Open Access
- 12 May 2021
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 48 (10) , 1266-1276
Skin manifestations as potential symptoms of diffuse vascular injury in criticalCOVID‐19 patients
As a respiratory viral infection caused by a novel coronavirus, COVID‐19 became rapidly pandemic within a few months. Despite the wide range of manifestations and organ involvement in COVID‐19 patients, the exact pathogenesis of severe and fatal types of COVID‐19 and causes involved with the individual base of the disease is not yet understood. Several studies have reported clinical, laboratory, and histopathological data in favor of vascular injury in multiple organs of critically ill patients with COVID‐19 as a result of hyperactive immune response, inflammation, and cytokine storm. Also, both clinical and histopathological evidence points to such vascular involvements in the skin. Given the ease of clinical examinations and skin biopsy and the lower risks of transmission of COVID‐19 to healthcare workers, the present review article was conducted to investigate the vascular skin manifestations of COVID‐19 patients clinically and/or histopathologically as helpful clues for better understanding the pathogenesis and predicting the prognosis of the disease, especially in severe cases.
- 12 May 2021
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 48 (10) , 1266-1276
Open AccessSkin manifestations as potential symptoms of diffuse vascular injury in criticalCOVID‐19 patients
As a respiratory viral infection caused by a novel coronavirus, COVID‐19 became rapidly pandemic within a few months. Despite the wide range of manifestations and organ involvement in COVID‐19 patients, the exact pathogenesis of severe and fatal types of COVID‐19 and causes involved with the individual base of the disease is not yet understood. Several studies have reported clinical, laboratory, and histopathological data in favor of vascular injury in multiple organs of critically ill patients with COVID‐19 as a result of hyperactive immune response, inflammation, and cytokine storm. Also, both clinical and histopathological evidence points to such vascular involvements in the skin. Given the ease of clinical examinations and skin biopsy and the lower risks of transmission of COVID‐19 to healthcare workers, the present review article was conducted to investigate the vascular skin manifestations of COVID‐19 patients clinically and/or histopathologically as helpful clues for better understanding the pathogenesis and predicting the prognosis of the disease, especially in severe cases.
- Open Access
- 11 May 2021
- Published by Wiley in Experimental Dermatology
- Vol. 30 (9) , 1233-1253
A systematic review of the histopathologic survey on skin biopsies in patients with Corona Virus Disease 2019 (COVID‐19) who developed virus or drug‐related mucocutaneous manifestations
The mucocutaneous manifestations of Corona Virus Disease 2019 (COVID‐19) logically may reflect systemic visceral involvements. These findings are visible and easy to approach like biopsies for exact histopathologic evaluations. This systematic review was conducted to collect the mucocutaneous histopathologic data of COVID‐19 patients for future investigations and interpretations. The COVID‐19 dermatology resource of the Centre of Evidence‐Based Dermatology (CEBD) at the University of Nottingham, PubMed, Scopus, Google Scholar and Medscape was searched for relevant English articles published by June 3, 2020. This review included 31 articles, involving 459 patients. The common primary virus‐related mucocutaneous manifestations are easy to approach in the course of COVID‐19. The authors of this study supposed dermatopathological findings as the predictors of the nature of potential systemic involvements and outcomes of COVID‐19. Scrutinizing these findings can help with adopting more effective therapeutic and management strategies; nevertheless, this review found the severity and time of onset of symptoms not to be associated with the laboratory and histopathological findings. Deterioration of clinical conditions and laboratory tests was also not related to the histopathological findings. It is recommended that meta‐analyses be conducted in the future to detail on these data for having more comprehensive and better conclusion.
- 11 May 2021
- Published by Wiley in Experimental Dermatology
- Vol. 30 (9) , 1233-1253
Open AccessA systematic review of the histopathologic survey on skin biopsies in patients with Corona Virus Disease 2019 (COVID‐19) who developed virus or drug‐related mucocutaneous manifestations
The mucocutaneous manifestations of Corona Virus Disease 2019 (COVID‐19) logically may reflect systemic visceral involvements. These findings are visible and easy to approach like biopsies for exact histopathologic evaluations. This systematic review was conducted to collect the mucocutaneous histopathologic data of COVID‐19 patients for future investigations and interpretations. The COVID‐19 dermatology resource of the Centre of Evidence‐Based Dermatology (CEBD) at the University of Nottingham, PubMed, Scopus, Google Scholar and Medscape was searched for relevant English articles published by June 3, 2020. This review included 31 articles, involving 459 patients. The common primary virus‐related mucocutaneous manifestations are easy to approach in the course of COVID‐19. The authors of this study supposed dermatopathological findings as the predictors of the nature of potential systemic involvements and outcomes of COVID‐19. Scrutinizing these findings can help with adopting more effective therapeutic and management strategies; nevertheless, this review found the severity and time of onset of symptoms not to be associated with the laboratory and histopathological findings. Deterioration of clinical conditions and laboratory tests was also not related to the histopathological findings. It is recommended that meta‐analyses be conducted in the future to detail on these data for having more comprehensive and better conclusion.
- 12 December 2020
- Published by Wiley in Dermatologic Therapy
- Vol. 34 (1) , e14669
Phosphodiesterase inhibitors and prostaglandin analogues in dermatology: A comprehensive review
Background and Objectives Due to immune‐mediated nature, medicines with immunomodulatory and anti‐inflammatory effects can used to treat many dermatologic diseases. Phosphodiesterase and prostaglandins are involved in many inflammatory pathways that cause cutaneous disorders. Phosphodiesterase inhibitors (PDEIs) and prostaglandin analogues are currently employed to treat several dermatologic disorders. Given the few comprehensive reviews in this context, focusing on the dermatologic applications and efficacy of these medicines appears valuable. The present comprehensive review was therefore performed on the applications of PDEIs and prostaglandin analogues in different cutaneous disorders. Methods All the relevant articles were selected to perform this review by searching databases such as Medline, Google Scholar, Scopus and Web of Science. Results Oral PDEIs, especially apremilast, is an effective medicine in psoriasis and a number of other cutaneous disorders such as vitiligo. Topical PDEIs, including crisaborole ointment 2%, is a safe and effective treatment in atopic dermatitis. Prostaglandin analogues, especially their topical forms such as latanoprost and bimatoprost, have different applications in cutaneous disorders, including pigmentary disorders, especially vitiligo and hair repigmentation; for instance, bimatoprost is used for eyelash repigmentation. Prostaglandin analogues are also used in alopecia, including androgenetic alopecia and alopecia areata. Conclusion Oral (apremilast) and topical (crisaborole) PDEIs and topical prostaglandin analogues, including latanoprost and bimatoprost, were found safe and effective in different skin diseases. In terms of efficiency and safety, these medicines compete with other medications of similar use even with higher efficacy and fewer side effects that necessitate further studies.
- 12 December 2020
- Published by Wiley in Dermatologic Therapy
- Vol. 34 (1) , e14669
Phosphodiesterase inhibitors and prostaglandin analogues in dermatology: A comprehensive review
Background and Objectives Due to immune‐mediated nature, medicines with immunomodulatory and anti‐inflammatory effects can used to treat many dermatologic diseases. Phosphodiesterase and prostaglandins are involved in many inflammatory pathways that cause cutaneous disorders. Phosphodiesterase inhibitors (PDEIs) and prostaglandin analogues are currently employed to treat several dermatologic disorders. Given the few comprehensive reviews in this context, focusing on the dermatologic applications and efficacy of these medicines appears valuable. The present comprehensive review was therefore performed on the applications of PDEIs and prostaglandin analogues in different cutaneous disorders. Methods All the relevant articles were selected to perform this review by searching databases such as Medline, Google Scholar, Scopus and Web of Science. Results Oral PDEIs, especially apremilast, is an effective medicine in psoriasis and a number of other cutaneous disorders such as vitiligo. Topical PDEIs, including crisaborole ointment 2%, is a safe and effective treatment in atopic dermatitis. Prostaglandin analogues, especially their topical forms such as latanoprost and bimatoprost, have different applications in cutaneous disorders, including pigmentary disorders, especially vitiligo and hair repigmentation; for instance, bimatoprost is used for eyelash repigmentation. Prostaglandin analogues are also used in alopecia, including androgenetic alopecia and alopecia areata. Conclusion Oral (apremilast) and topical (crisaborole) PDEIs and topical prostaglandin analogues, including latanoprost and bimatoprost, were found safe and effective in different skin diseases. In terms of efficiency and safety, these medicines compete with other medications of similar use even with higher efficacy and fewer side effects that necessitate further studies.